SPECIAL REPORT

Click here to complete the quick poll on DMT preferences.
Submit your responses anonymously to be able to view the aggregate results of the poll.

Patient satisfaction with high-efficacy therapies
Switching therapies
Real-world impact on PIRA

Over 12,000 MS patients in Canada have been treated with ofatumumab, an anti-CD20 monoclonal antibody administered by self-injection, since it was authorized for use five years ago. A Canadian study has now examined patient acceptance of treatment in an analysis of patient support program (PSP) data (Selchen et al. Mult Scler Relat Disord 2026:107:106976). A total of 5436 of 6377 patients in the database met inclusion criteria. Treatment persistence was 96.94% at 12 months, 95.02% at 24 months and 92.26% at 36 months. The most common reasons for treatment discontinuation were side effects (0.9%), conception/pregnancy (0.5%) and patient request (0.5%). Read More

Anti-CD20 therapies for multiple sclerosis have come to dominate the therapeutic (and publishing) landscape. Thus far in 2026, six studies have compared the relative efficacy and safety of ocrelizumab and rituximab. Read More